Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$30.54
-1.1%
$30.60
$26.25
$40.49
$15.67B0.634.48 million shs2.72 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$86.98
+1.9%
$74.23
$57.52
$128.63
$34.11B1.434.37 million shs2.86 million shs
Insulet Co. stock logo
PODD
Insulet
$323.55
-0.9%
$274.57
$171.61
$329.33
$22.77B1.26710,674 shs919,836 shs
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$211.52
+0.2%
$211.94
$187.43
$352.33
$15.20B1.14726,467 shs424,153 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
+2.40%-1.84%+2.25%-12.32%-8.91%
DexCom, Inc. stock logo
DXCM
DexCom
+0.97%-2.30%+19.08%-5.09%-33.01%
Insulet Co. stock logo
PODD
Insulet
+1.64%-0.25%+25.29%+20.69%+81.40%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
+2.52%-2.16%-1.73%-3.99%-36.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.4633 of 5 stars
2.25.01.74.01.71.72.5
DexCom, Inc. stock logo
DXCM
DexCom
4.7445 of 5 stars
3.54.00.04.73.02.51.9
Insulet Co. stock logo
PODD
Insulet
4.1826 of 5 stars
2.43.00.04.94.00.81.9
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
4.7763 of 5 stars
3.55.01.73.23.01.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.44
Hold$37.2521.98% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.0012.67% Upside
Insulet Co. stock logo
PODD
Insulet
2.82
Moderate Buy$309.88-4.22% Downside
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
3.00
Buy$332.5057.20% Upside

Current Analyst Ratings Breakdown

Latest WST, DXCM, BAX, and PODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Insulet Co. stock logo
PODD
Insulet
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$328.00 ➝ $360.00
5/22/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/22/2025
Insulet Co. stock logo
PODD
Insulet
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $380.00
5/16/2025
Insulet Co. stock logo
PODD
Insulet
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/13/2025
Insulet Co. stock logo
PODD
Insulet
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$350.00
5/9/2025
Insulet Co. stock logo
PODD
Insulet
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$312.00 ➝ $324.00
5/5/2025
Baxter International Inc. stock logo
BAX
Baxter International
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$30.00 ➝ $28.00
5/5/2025
DexCom, Inc. stock logo
DXCM
DexCom
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.00
5/2/2025
Baxter International Inc. stock logo
BAX
Baxter International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$36.00 ➝ $33.00
5/2/2025
DexCom, Inc. stock logo
DXCM
DexCom
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $90.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$10.77B1.45$4.73 per share6.45$16.69 per share1.83
DexCom, Inc. stock logo
DXCM
DexCom
$4.15B8.22$2.19 per share39.75$5.38 per share16.17
Insulet Co. stock logo
PODD
Insulet
$2.20B10.36$4.26 per share75.96$10.49 per share30.84
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$2.90B5.25$9.36 per share22.60$37.10 per share5.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
-$649M-$1.10N/A11.190.93-5.05%16.67%4.93%8/5/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3460.8335.362.3014.29%30.14%10.11%7/24/2025 (Estimated)
Insulet Co. stock logo
PODD
Insulet
$206.30M$5.5655.8865.103.6220.19%24.46%8.33%8/14/2025 (Estimated)
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$492.70M$6.3731.6226.916.7417.03%18.60%13.80%7/24/2025 (Estimated)

Latest WST, DXCM, BAX, and PODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Insulet Co. stock logo
PODD
Insulet
$0.81$1.02+$0.21$0.50$543.20 million$569.00 million
5/1/2025Q1 2025
Baxter International Inc. stock logo
BAX
Baxter International
$0.48$0.62+$0.14$0.25$2.59 billion$2.63 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/24/2025Q1 2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.22$1.45+$0.23$1.23$685.24 million$698.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$0.682.23%-1.40%N/A N/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$0.840.40%-4.48%13.19%N/A

Latest WST, DXCM, BAX, and PODD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
quarterly$0.210.39%7/30/20257/30/20258/6/2025
5/6/2025
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.172.27%5/30/20255/30/20257/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.31
1.43
1.09
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
Insulet Co. stock logo
PODD
Insulet
1.21
3.68
2.80
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.08
2.79
2.23

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Insulet Co. stock logo
PODD
Insulet
N/A
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
93.90%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.21%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Insulet Co. stock logo
PODD
Insulet
0.39%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
60,000513.18 million509.47 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600392.11 million389.60 millionOptionable
Insulet Co. stock logo
PODD
Insulet
2,60070.38 million69.82 millionOptionable
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
10,70071.85 million71.92 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Baxter International stock logo

Baxter International NYSE:BAX

$30.54 -0.33 (-1.08%)
Closing price 03:59 PM Eastern
Extended Trading
$31.26 +0.72 (+2.36%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

DexCom stock logo

DexCom NASDAQ:DXCM

$86.98 +1.65 (+1.93%)
Closing price 04:00 PM Eastern
Extended Trading
$87.74 +0.75 (+0.87%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Insulet stock logo

Insulet NASDAQ:PODD

$323.55 -3.09 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$323.38 -0.17 (-0.05%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

West Pharmaceutical Services stock logo

West Pharmaceutical Services NYSE:WST

$211.52 +0.50 (+0.24%)
Closing price 03:59 PM Eastern
Extended Trading
$209.98 -1.55 (-0.73%)
As of 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.